Serum HBV RNA is associated with liver fibrosis regression in HBeAg ‐positive chronic hepatitis B patients treated with nucleos(t)ide analogues
Journal of Viral Hepatitis · 2023
DOI: 10.1111/jvh.13790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2023. Verfasst von Dandan Bian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Liver Disease Center, Beijing YouAn Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Hepatitis B virus, Hepatitis B, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Noninvasive methods for assessing hepatic fibrosis are clinically necessary. This study aims to explore HBV markers correlated with liver fibrosis and capable of diagnosing significant fibrosis and predicting fibrosis regression. Seventy‐four HBeAg‐positive chronic hepatitis B (CHB) patients were enrolled and started on entecavir or adefovir therapy. Serum HBV RNA, HBV DNA, HBsAg and hepatitis B core‐related antigen (HBcrAg) levels were measured at baseline and during treatment. Liver fibrosis was assessed at baseline and month 60 by liver biopsy. Fibrosis regression was defined as Ishak fibrosis score decreased ≥1‐point. At baseline, HBsAg, HBcrAg and HBV RNA levels had a stronger correlation with Ishak fibrosis score ( r = −.441, p = .002; r = −.469, p = .001; r = −.398, p = .001) than APRI and FIB‐4 ( r = .321 p = .006; r = .371, p = .001). HBsAg >4 log 10 IU/ml plus HBcrAg >7 log 10 IU/ml or HBsAg >4 log 10 IU/ml plus HBV RNA >5 log 10 copies/ml exhibited the same excellent diagnostic ability for significant fibrosis with the AUROC of 0.857. After 60 months of antiviral treatment, 66.7% of patients who suffered significant fibrosis at baseline achieved fibrosis regression, and an HBV RNA decline from baseline to month 6 greater than 0.63 log 10 copies/ml could predict the fibrosis regression at month 60. In conclusion , serum HBsAg, HBcrAg and HBV RNA are potential markers for predicting significant liver fibrosis. HBV RNA measurement would be particularly useful for monitoring hepatic fibrosis changes in HBeAg‐positive CHB patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Disease Center, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
- Department of Infectious Diseases, Electric Power Teaching Hospital, Capital Medical University, Beijing, China.
- Department of Microbiology and Infectious Disease Center, Peking University Health Science Center, Beijing, China.
- Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China.
Förderung
- Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Bian, D., Zhao, J., Liao, H., Wang, Y., Ren, Y., Jiang, Y., Liu, S., Chen, X., Hu, Z., Duan, Z., Lu, F., & Zheng, S. (2023). Serum HBV RNA is associated with liver fibrosis regression in HBeAg ‐positive chronic hepatitis B patients treated with nucleos(t)ide analogues. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13790
Vancouver
Bian D, Zhao J, Liao H, Wang Y, Ren Y, Jiang Y, et al. Serum HBV RNA is associated with liver fibrosis regression in HBeAg ‐positive chronic hepatitis B patients treated with nucleos(t)ide analogues. Journal of Viral Hepatitis. 2023. doi:10.1111/jvh.13790
BibTeX
@article{Bian2023,
author = {Bian, Dandan and Zhao, Jing and Liao, Hao and Wang, Yang and Ren, Yan and Jiang, Yingying and Liu, Shuang and Chen, Xinyue and Hu, Zhongjie and Duan, Zhongping and Lu, Fengmin and Zheng, Sujun},
title = {Serum HBV RNA is associated with liver fibrosis regression in HBeAg ‐positive chronic hepatitis B patients treated with nucleos(t)ide analogues},
journal = {Journal of Viral Hepatitis},
year = {2023},
doi = {10.1111/jvh.13790}
}
EUVIMED